A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-Related Macular Degeneration
After 4 years of treatment with ranibizumab for neovascular age-related macular degeneration, one third of the 600 eyes had stable visual acuity with continuous treatment; the remainder required follow-up to detect recurrent or new disease.
View the current issue of Ophthalmology.
Is DMEK on the Rise? How This Evolving Surgery Compares With DSAEK
Although indications for these procedures are similar, each has unique benefits and drawbacks.
Five experts look at DMEK and DSAEK—their learning curves, visual results, rejection rates, and attachment challenges—and illuminate the strengths and weaknesses of the newer procedure relative to DSAEK.
View the current issue of EyeNet.
Manage Your Subscriptions